<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36759009</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2056-5933</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>RMD open</Title><ISOAbbreviation>RMD Open</ISOAbbreviation></Journal><ArticleTitle>Lipid management in systemic lupus erythematosus according to risk classifiers suggested by the European Society of Cardiology and disease-related risk factors reported by the EULAR recommendations.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e002767</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/rmdopen-2022-002767</ELocationID><Abstract><AbstractText Label="BACKGROUND">The European Alliance of Associations for Rheumatology recommended that lipid-lowering therapy (LLT) in systemic lupus erythematosus (SLE) should follow general population guidelines. We examined the eligibility for LLT in SLE according to Systematic Coronary Risk Evaluation (SCORE), with and without the addition of vascular ultrasound (VUS) and disease-related features.</AbstractText><AbstractText Label="METHODS">210 patients with SLE without prior cardiovascular events, diabetes or antiphospholipid syndrome underwent cardiovascular risk assessment with SCORE. LLT eligibility was evaluated in low-risk and moderate-risk patients following European Society of Cardiology (ESC) guidelines. Atherosclerotic plaques on carotid ultrasound (cUS)) and carotid and femoral ultrasound (cfUS), prolonged disease duration (PDD, &#x2265;10 years), failure to achieve lupus low disease activity state (LLDAS<sub>no</sub>), cumulative glucocorticoid 'cardiovascular harm' dose (GC<sub>CVH</sub>, optimal cut-off to predict ultrasound-detected plaques) and antiphospholipid antibody positivity (aPL<sub>pos</sub>) were tested as SCORE risk enhancers for classification ability (phi coefficient) and agreement (Cohen's kappa) using SCORE plus cfUS as a reference modality for LLT eligibility.</AbstractText><AbstractText Label="RESULTS">Plaques were detected in 9.9% of low-risk cases and 54.6% of moderate-risk cases. SCORE alone would indicate 0% of low-risk patients and 3% of moderate-risk patients for LLT eligibility. According to SCORE+cfUS, 9.9% of low-risk patients and 57.6% of moderate-risk patients, respectively, would be eligible for LLT based on ESC guidelines. &#x399;n low-risk/moderate-risk patients, phi values for SCORE+PDD, GC<sub>CVH</sub> (cut-off &#x2265;11&#x2009;g), LLDAS<sub>no</sub> and aPL<sub>pos</sub> in antiplatelet-na&#xef;ve antiphospholipid antibody-positive (aPL<sub>pos</sub>/<sub>APT-</sub>) cases were 0.06/0.13, 0.23/0.20, 0.07/0.16 and 0.06/0.33, respectively. Agreement for LLT eligibility to SCORE+cfUS was better for SCORE+PDD in moderate-risk patients and for SCORE+cUS in both groups of patients. SCORE+GC<sub>CVH</sub>&#x2009;and SCORE+aPL<sub>pos</sub> showed at least fair agreement (kappa &#x2265;0.20) to SCORE+cfUS in low-risk or moderate-risk and in aPL<sub>pos</sub>/APT- moderate-risk patients, respectively.</AbstractText><AbstractText Label="CONCLUSION">Disease-related and VUS features, in addition to SCORE, may help to improve LLT decision making in SLE. GC<sub>CVH</sub> and aPL<sub>pos</sub> improve LLT eligibility similarly and to a greater degree than PDD or LLDAS<sub>no</sub>.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Drosos</LastName><ForeName>George C</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Cardiovascular Risk Research Laboratory, First Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konstantonis</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiovascular Risk Research Laboratory, First Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sfikakis</LastName><ForeName>Petros P</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Cardiovascular Risk Research Laboratory, First Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology Unit, First Department of Propaedeutic and Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tektonidou</LastName><ForeName>Maria G</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0003-2238-0975</Identifier><AffiliationInfo><Affiliation>Cardiovascular Risk Research Laboratory, First Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece mtektonidou@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology Unit, First Department of Propaedeutic and Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RMD Open</MedlineTA><NlmUniqueID>101662038</NlmUniqueID><ISSNLinking>2056-5933</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017152">Antibodies, Antiphospholipid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058226" MajorTopicYN="Y">Plaque, Atherosclerotic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017152" MajorTopicYN="N">Antibodies, Antiphospholipid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002309" MajorTopicYN="Y">Cardiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atherosclerosis</Keyword><Keyword MajorTopicYN="N">Cardiovascular Disease</Keyword><Keyword MajorTopicYN="N">Lipids</Keyword><Keyword MajorTopicYN="N">Systemic Lupus Erythematosus</Keyword><Keyword MajorTopicYN="N">Ultrasonography</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>9</Day><Hour>20</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36759009</ArticleId><ArticleId IdType="pmc">PMC9923358</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2022-002767</ArticleId><ArticleId IdType="pii">rmdopen-2022-002767</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yazdany J, Pooley N, Langham J, et al. . Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis. RMD Open 2020;6:e001247. 10.1136/rmdopen-2020-001247</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2020-001247</ArticleId><ArticleId IdType="pmc">PMC7722272</ArticleId><ArticleId IdType="pubmed">32900883</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Wang Z, Ward MM. Brief report: trends in hospitalizations due to acute coronary syndromes and stroke in patients with systemic lupus erythematosus, 1996 to 2012. Arthritis Rheumatol 2016;68:2680&#x2013;5. 10.1002/art.39758</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39758</ArticleId><ArticleId IdType="pmc">PMC5083218</ArticleId><ArticleId IdType="pubmed">27273732</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YH, Choi SJ, Ji JD, et al. . Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus 2016;25:727&#x2013;34. 10.1177/0961203315627202</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315627202</ArticleId><ArticleId IdType="pubmed">26811368</ArticleId></ArticleIdList></Reference><Reference><Citation>Drosos GC, Vedder D, Houben E, et al. . EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 2022;81:768&#x2013;79. 10.1136/annrheumdis-2021-221733</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221733</ArticleId><ArticleId IdType="pubmed">35110331</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Alunno A, et al. . 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019;78:736&#x2013;45. 10.1136/annrheumdis-2019-215089</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Tselios K, Sheane BJ, Gladman DD, et al. . Optimal monitoring for coronary heart disease risk in patients with systemic lupus erythematosus: a systematic review. J Rheumatol 2016;43:54&#x2013;65. 10.3899/jrheum.150460</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.150460</ArticleId><ArticleId IdType="pubmed">26568591</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikpour M, Gladman DD, Ibanez D, et al. . Assessment of coronary risk based on cumulative exposure to lipids in systemic lupus erythematosus. J Rheumatol 2013;40:2006&#x2013;14. 10.3899/jrheum.121273</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.121273</ArticleId><ArticleId IdType="pubmed">24128779</ArticleId></ArticleIdList></Reference><Reference><Citation>Masson W, Rossi E, Mora-Crespo LM, et al. . Cardiovascular risk stratification and appropriate use of statins in patients with systemic lupus erythematosus according to different strategies. Clin Rheumatol 2020;39:455&#x2013;62. 10.1007/s10067-019-04856-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-019-04856-z</ArticleId><ArticleId IdType="pubmed">31802350</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SK, Barbhaiya M, Fischer MA, et al. . Lipid testing and statin prescriptions among Medicaid recipients with systemic lupus erythematosus or diabetes mellitus and the general Medicaid population. Arthritis Care Res (Hoboken) 2019;71:104&#x2013;15. 10.1002/acr.23574</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23574</ArticleId><ArticleId IdType="pmc">PMC6185821</ArticleId><ArticleId IdType="pubmed">29648687</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Herz A, Ensworth S, Shojania K, et al. . Cardiovascular risk factor screening in systemic lupus erythematosus. J Rheumatol 2003;30:493&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12610807</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeilbeigi F, Pope JE. Appropriate cardiovascular disease risk assessment in systemic lupus erythematosus may be lacking in rheumatology practice. Clin Exp Rheumatol 2018;36:526&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">29846162</ArticleId></ArticleIdList></Reference><Reference><Citation>Mach F, Baigent C, Catapano AL, et al. . 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111&#x2013;88. 10.1093/eurheartj/ehz455</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz455</ArticleId><ArticleId IdType="pubmed">31504418</ArticleId></ArticleIdList></Reference><Reference><Citation>Conroy RM, Py&#xf6;r&#xe4;l&#xe4; K, Fitzgerald AP, et al. . Estimation of ten-year risk of fatal cardiovascular disease in Europe: the score project. Eur Heart J 2003;24:987&#x2013;1003. 10.1016/s0195-668x(03)00114-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0195-668x(03)00114-3</ArticleId><ArticleId IdType="pubmed">12788299</ArticleId></ArticleIdList></Reference><Reference><Citation>Piepoli MF, Hoes AW, Agewall S, et al. . 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint Task force of the European Society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European association for cardiovascular prevention &amp; rehabilitation (eacpr). Eur Heart J 2016;37:2315&#x2013;81. 10.1093/eurheartj/ehw106</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw106</ArticleId><ArticleId IdType="pmc">PMC4986030</ArticleId><ArticleId IdType="pubmed">27222591</ArticleId></ArticleIdList></Reference><Reference><Citation>Drosos GC, Konstantonis G, Sfikakis PP, et al. . Underperformance of clinical risk scores in identifying vascular ultrasound-based high cardiovascular risk in systemic lupus erythematosus. Eur J Prev Cardiol 2021;28:346&#x2013;52. 10.1093/eurjpc/zwaa256</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjpc/zwaa256</ArticleId><ArticleId IdType="pubmed">33891687</ArticleId></ArticleIdList></Reference><Reference><Citation>Quevedo-Abeledo JC, Palazuelos C, Llorca J, et al. . POS0728 QRISK3 relation to carotid plaque is higher than that of score in patients with systemic lupus erythematosus. Ann Rheum Dis 2021;80(Suppl 1):614. 10.1136/annrheumdis-2021-eular.1376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-eular.1376</ArticleId><ArticleId IdType="pubmed">34240117</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Kravvariti E, Konstantonis G, et al. . Subclinical atherosclerosis in systemic lupus erythematosus: comparable risk with diabetes mellitus and rheumatoid arthritis. Autoimmun Rev 2017;16:308&#x2013;12. 10.1016/j.autrev.2017.01.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2017.01.009</ArticleId><ArticleId IdType="pubmed">28147263</ArticleId></ArticleIdList></Reference><Reference><Citation>Frerix M, Stegbauer J, Kreuter A, et al. . Atherosclerotic plaques occur in absence of intima-media thickening in both systemic sclerosis and systemic lupus erythematosus: a duplexsonography study of carotid and femoral arteries and follow-up for cardiovascular events. Arthritis Res Ther 2014;16:R54. 10.1186/ar4489</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4489</ArticleId><ArticleId IdType="pmc">PMC3978872</ArticleId><ArticleId IdType="pubmed">24548804</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai A-M, Alarc&#xf3;n GS, et al. . Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677&#x2013;86. 10.1002/art.34473</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Andreoli L, Limper M, et al. . EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019;78:1296&#x2013;304. 10.1136/annrheumdis-2019-215213</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215213</ArticleId><ArticleId IdType="pubmed">31092409</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakis S, Lockshin MD, Atsumi T, et al. . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295&#x2013;306. 10.1111/j.1538-7836.2006.01753.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2006.01753.x</ArticleId><ArticleId IdType="pubmed">16420554</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklyn K, Lau CS, Navarra SV, et al. . Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis 2016;75:1615&#x2013;21. 10.1136/annrheumdis-2015-207726</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207726</ArticleId><ArticleId IdType="pubmed">26458737</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams B, Mancia G, Spiering W, et al. . 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021&#x2013;104. 10.1093/eurheartj/ehy339</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy339</ArticleId><ArticleId IdType="pubmed">30165516</ArticleId></ArticleIdList></Reference><Reference><Citation>Touboul P-J, Hennerici MG, Meairs S, et al. . Mannheim carotid intima-media thickness and plaque consensus (2004&#x2013;2006&#x2013;2011). Cerebrovasc Dis 2012;34:290&#x2013;6. 10.1159/000343145</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000343145</ArticleId><ArticleId IdType="pmc">PMC3760791</ArticleId><ArticleId IdType="pubmed">23128470</ArticleId></ArticleIdList></Reference><Reference><Citation>Agca R, Heslinga SC, Rollefstad S, et al. . EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017;76:17&#x2013;28. 10.1136/annrheumdis-2016-209775</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-209775</ArticleId><ArticleId IdType="pubmed">27697765</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballocca F, D&#x2019;Ascenzo F, Moretti C, et al. . Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol 2015;22:1435&#x2013;41. 10.1177/2047487314546826</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2047487314546826</ArticleId><ArticleId IdType="pubmed">25139772</ArticleId></ArticleIdList></Reference><Reference><Citation>Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol 2012;176:708&#x2013;19. 10.1093/aje/kws130</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kws130</ArticleId><ArticleId IdType="pmc">PMC3571250</ArticleId><ArticleId IdType="pubmed">23024137</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Mak A, Leong J, et al. . Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci Med 2021;8:e000590. 10.1136/lupus-2021-000590</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000590</ArticleId><ArticleId IdType="pmc">PMC8689160</ArticleId><ArticleId IdType="pubmed">34930819</ArticleId></ArticleIdList></Reference><Reference><Citation>Chicco D, Jurman G. The advantages of the matthews correlation coefficient (MCC) over F1 score and accuracy in binary classification evaluation. BMC Genomics 2020;21:6. 10.1186/s12864-019-6413-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12864-019-6413-7</ArticleId><ArticleId IdType="pmc">PMC6941312</ArticleId><ArticleId IdType="pubmed">31898477</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossello X, Dorresteijn JA, Janssen A, et al. . Risk prediction tools in cardiovascular disease prevention: A report from the ESC prevention of CVD programme led by the european association of preventive cardiology (EAPC) in collaboration with the acute cardiovascular care association (ACCA) and the association of cardiovascular nursing and allied professions (ACNAP). Eur J Prev Cardiol 2019;26:1534&#x2013;44. 10.1177/2047487319846715</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2047487319846715</ArticleId><ArticleId IdType="pubmed">31234648</ArticleId></ArticleIdList></Reference><Reference><Citation>Ocon AJ, Reed G, Pappas DA, et al. . Short-Term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis. Ann Rheum Dis 2021;80:1522&#x2013;9. 10.1136/annrheumdis-2021-220577</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220577</ArticleId><ArticleId IdType="pubmed">34215644</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG. Cardiovascular disease risk in antiphospholipid syndrome: thrombo-inflammation and atherothrombosis. J Autoimmun 2022;128:102813. 10.1016/j.jaut.2022.102813</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2022.102813</ArticleId><ArticleId IdType="pubmed">35247655</ArticleId></ArticleIdList></Reference><Reference><Citation>Kooter AJ, Kostense PJ, Groenewold J, et al. . Integrating information from novel risk factors with calculated risks: the critical impact of risk factor prevalence. Circulation 2011;124:741&#x2013;5. 10.1161/CIRCULATIONAHA.111.035725</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.111.035725</ArticleId><ArticleId IdType="pubmed">21824935</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri MA, Barr E, Magder LS. Development of a systemic lupus erythematosus cardiovascular risk equation. Lupus Sci Med 2019;6:e000346. 10.1136/lupus-2019-000346</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2019-000346</ArticleId><ArticleId IdType="pmc">PMC6827738</ArticleId><ArticleId IdType="pubmed">31749976</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivakumaran J, Harvey P, Omar A, et al. . Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus. Lupus Sci Med 2021;8:e000448. 10.1136/lupus-2020-000448</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000448</ArticleId><ArticleId IdType="pmc">PMC8162102</ArticleId><ArticleId IdType="pubmed">34045359</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>